Osaka, Japan - October 5, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Dutasteride Capsules (the branded product: ZAGALLO®).
Dutasteride Capsules are prescribed for the treatment of male pattern alopecia.
The product approved by MHLW on October 5
|Product Name||Dutasteride Capsules ZA 0.5 mg [SAWAI]|
|Brand products||ZAGALLO® Capsules 0.5 mg|
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.